Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oligodendroglial markers in the cuprizone model of CNS de- and remyelination.
Salinas Tejedor L, Gudi V, Kucman V, Pul R, Gingele S, Sühs KW, Stangel M, Skripuletz T. Salinas Tejedor L, et al. Among authors: skripuletz t. Histol Histopathol. 2015 Dec;30(12):1455-64. doi: 10.14670/HH-11-640. Epub 2015 Jun 25. Histol Histopathol. 2015. PMID: 26110560
Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system.
Salinas Tejedor L, Berner G, Jacobsen K, Gudi V, Jungwirth N, Hansmann F, Gingele S, Prajeeth CK, Baumgärtner W, Hoffmann A, Skripuletz T, Stangel M. Salinas Tejedor L, et al. Among authors: skripuletz t. Brain Behav Immun. 2015 Nov;50:155-165. doi: 10.1016/j.bbi.2015.06.024. Epub 2015 Jun 30. Brain Behav Immun. 2015. PMID: 26140734
Intraspinal cavernous bleeding during early pregnancy.
Pars K, Garde N, Conzen J, Pul R, Dengler R, Stangel M, Skripuletz T, Trebst C. Pars K, et al. Among authors: skripuletz t. J Neurol. 2016 Oct;263(10):2127-9. doi: 10.1007/s00415-016-8245-6. Epub 2016 Aug 3. J Neurol. 2016. PMID: 27488862 No abstract available.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
204 results